Cargando…

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience

SIMPLE SUMMARY: The use of carfilzomib in multiple myeloma is burdened by cardiovascular toxicity. Currently, the risk stratification of cardiovascular adverse events appears well established, while the prognosis of patients classified as being at high risk or experiencing adverse events is uncertai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mingrone, Giulia, Astarita, Anna, Colomba, Anna, Catarinella, Cinzia, Cesareo, Marco, Airale, Lorenzo, Paladino, Arianna, Leone, Dario, Vallelonga, Fabrizio, Bringhen, Sara, Gay, Francesca, Veglio, Franco, Milan, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953901/ https://www.ncbi.nlm.nih.gov/pubmed/36831492 http://dx.doi.org/10.3390/cancers15041149

Ejemplares similares

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
por: Astarita, Anna, et al.
Publicado: (2021)

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
por: Mingrone, Giulia, et al.
Publicado: (2021)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
por: Bruno, Giulia, et al.
Publicado: (2019)

Cardiovascular Hypertension-Mediated Organ Damage in Hypertensive Urgencies and Hypertensive Outpatients
por: Vallelonga, Fabrizio, et al.
Publicado: (2022)

A Novel Approach to Left Ventricular Filling Pressure Assessment: The Role of Hemodynamic Forces Analysis
por: Airale, Lorenzo, et al.
Publicado: (2021)

Accuracy of a Symptom-Based Approach to Identify Hypertensive Emergencies in the Emergency Department
por: Vallelonga, Fabrizio, et al.
Publicado: (2020)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

Introduction to Hemodynamic Forces Analysis: Moving Into the New Frontier of Cardiac Deformation Analysis
por: Vallelonga, Fabrizio, et al.
Publicado: (2021)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
por: Harvey, R Donald
Publicado: (2014)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
por: Chari, Ajai, et al.
Publicado: (2014)

Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population
por: Doran, Stacey, et al.
Publicado: (2023)

The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS
por: Watanabe, Motoko, et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
por: Yang, Jenny Z., et al.
Publicado: (2021)

Long-term cardiovascular adverse events in very elderly COVID-19 patients
por: Karadavut, Serhat, et al.
Publicado: (2022)

Novel transformations for very high multiplicity events
por: Drevermann, H, et al.
Publicado: (1997)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

Adverse Drug Events and Associated Factors in Heart Failure Therapy Among the Very Elderly
por: Sztramko, Richard, et al.
Publicado: (2011)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Response to “Evaluating Adverse Events in Databases”
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Central Pressure Appraisal: Clinical Validation of a Subject-Specific Mathematical Model
por: Tosello, Francesco, et al.
Publicado: (2016)

Correction: Central Pressure Appraisal: Clinical Validation of a Subject-Specific Mathematical Model
por: Tosello, Francesco, et al.
Publicado: (2016)

Hypertensive emergencies and urgencies: a preliminary report of the ongoing Italian multicentric study ERIDANO
por: Vallelonga, Fabrizio, et al.
Publicado: (2023)

Analysis of multicenter clinical trials with very low event rates
por: Kim, Jiyu, et al.
Publicado: (2020)

Adverse event reporting in adult intensive care units and the impact of a multifaceted intervention on drug-related adverse events
por: Pagnamenta, Alberto, et al.
Publicado: (2012)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
por: Barla, Ioanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p7sa1i8ve93drgebpn7sk811oo